Time to OccurrenceDecreases in Hemoglobin

8

0

16

24

32

Weeks

Percent of Patients at Risk

Marked decrease

( ?15% and < 11 g/dl)

Marked decrease

( ?15% and < 10 g/dl)

Decrease of ? 1 g/dl

Bosentan (N = 636)

Placebo (N = 271)

20

10

0

20

10

0

0

100

50

8 Placebo-controlled Studies

9082.01

Previous slide

Next slide

Back to first slide

View graphic version